Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Infection and Chemotherapy
Published in: Journal of Infection and Chemotherapy 5/2013

01-10-2013 | Case Report

Adjustment of antiretroviral regimen may lead to HBV reactivation even in patients with past HBV infection serological profile

Authors: Sophie Seang, Vincent Thibault, Marc Antoine Valantin, Christine Katlama

Published in: Journal of Infection and Chemotherapy | Issue 5/2013

Login to get access

Abstract

We report a reactivation of hepatitis B virus (HBV) in an human immunodeficiency virus (HIV) patient despite a serological profile of past HBV infection with anti-HBs and anti-HBc antibodies, following the interruption of tenofovir/emtricitabine. In HBV–HIV co-infected patients, close monitoring of HBV viral load and serological markers is required for antiretroviral management, particularly after interruption of drugs active for HBV.
Literature
1.
Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36.PubMedCrossRef
2.
Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857–65.PubMedCrossRef
3.
Bloquel B, Jeulin H, Burty C, Letranchant L, Rabaud C, Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol. 2010;82:206–12.PubMedCrossRef
4.
Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7:1130–7.PubMedCrossRef
5.
Ozaras R, Ar C, Ongoren S, Mete B, Tabak F, Mert A, et al. Acute hepatitis B despite a previous high titer of anti-HBs. Hepatol Int. 2010;4:530–2.PubMedCrossRef
6.
Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol. 2009;81:441–445.
7.
Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2001;32:144–8.PubMedCrossRef
8.
Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005;42:302–8.PubMedCrossRef
9.
Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol. 2006;37:206–12.PubMedCrossRef
10.
Terkmani H, Visseaux B, Poynard T, Thibault V. Anti-HBc antibody avidity determination allows rapid discrimination between acute hepatitis B and hepatitis B reactivation. Hepatology 2005;42(4):suppl 1.
Metadata
Title
Adjustment of antiretroviral regimen may lead to HBV reactivation even in patients with past HBV infection serological profile
Authors
Sophie Seang
Vincent Thibault
Marc Antoine Valantin
Christine Katlama
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 5/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-013-0560-6

Other articles of this Issue 5/2013

Journal of Infection and Chemotherapy 5/2013 Go to the issue

Original Article

Significance of anaerobic bacteria in postoperative infection after radical cystectomy and urinary diversion or reconstruction

Case Report

Relationship between the clinical efficacy and AUC/MIC of intravenous ciprofloxacin in Japanese patients with intraabdominal infections

Review Article

Vaccine chronicle in Japan

Case Report

Systemic inflammatory response syndrome and prolonged hypoperfusion lesions in an infant with respiratory syncytial virus encephalopathy

Note

Dissolution profile of 24 levofloxacin (100 mg) tablets

Case Report

Burkholderia contaminans: unusual cause of biliary sepsis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits